| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Timothy J Doherty | |
| Jeffrey B Hoag | |||
| Jason Lu | |||
| Mark E Lund | |||
| Rudolph E Willis | |||
| Aimel Azizi | |||
| P2860 | cites work | ErbB receptors: from oncogenes to targeted cancer therapies | Q24683709 |
| Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. | Q27824811 | ||
| Cetuximab for the treatment of colorectal cancer. | Q27851419 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. | Q51776233 | ||
| Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. | Q53861991 | ||
| Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head | Q56688854 | ||
| A Phase I Study of Cetuximab/Paclitaxel in Patients with Advanced-Stage Breast Cancer | Q57578464 | ||
| Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base | Q57949385 | ||
| A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer | Q57975564 | ||
| Safety-Related Regulatory Actions for Biologicals Approved in the United States and the European Union | Q63865834 | ||
| Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer | Q73877537 | ||
| Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy | Q79323220 | ||
| First-line single-agent cetuximab in patients with advanced colorectal cancer | Q80180429 | ||
| Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer | Q81323824 | ||
| A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study | Q81388294 | ||
| Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity | Q81547151 | ||
| Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm | Q82676913 | ||
| Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience | Q83194018 | ||
| Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck | Q29619277 | ||
| Cetuximab-associated infusion reactions: pathology and management | Q30230265 | ||
| Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial | Q33361488 | ||
| Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck | Q33371281 | ||
| Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study | Q33378256 | ||
| Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study | Q33379271 | ||
| Platinum-based chemotherapy plus cetuximab in head and neck cancer | Q33381094 | ||
| Radiation-induced lung disease and the impact of radiation methods on imaging features | Q33842848 | ||
| Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study | Q34471062 | ||
| Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. | Q34507119 | ||
| Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial | Q36614517 | ||
| Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines | Q36628049 | ||
| Incidence and management of cutaneous toxicities associated with cetuximab | Q36762448 | ||
| Clinical management of cutaneous toxicity of anti-EGFR agents. | Q36829698 | ||
| Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. | Q36858054 | ||
| Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. | Q37113071 | ||
| A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer. | Q37222532 | ||
| Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. | Q39986130 | ||
| Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer | Q40287803 | ||
| Biopharmaceutical benchmarks 2006. | Q40307417 | ||
| Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma | Q40446595 | ||
| Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer | Q40493345 | ||
| Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer | Q40600537 | ||
| Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. | Q43503018 | ||
| Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). | Q43604675 | ||
| Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab. | Q45997056 | ||
| Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. | Q46027726 | ||
| Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study | Q46347493 | ||
| Cetuximab with hepatic arterial infusion of chemotherapy for the treatment of colorectal cancer liver metastases. | Q46408816 | ||
| A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicities | Q46466734 | ||
| Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck | Q46595210 | ||
| Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. | Q46623103 | ||
| EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer | Q46662707 | ||
| A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. | Q46755325 | ||
| Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer | Q46772387 | ||
| Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer | Q46843394 | ||
| Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial | Q46852439 | ||
| Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas | Q46891324 | ||
| Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer | Q46892017 | ||
| Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. | Q46942430 | ||
| Safety and efficacy of cetuximab-chemotherapy combination in Saudi patients with metastatic colorectal cancer. | Q46949229 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cetuximab | Q420296 |
| monoclonal antibody | Q422248 | ||
| lung | Q7886 | ||
| neoplasm | Q1216998 | ||
| antineoplastic | Q2853144 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 113 | |
| P577 | publication date | 2009-08-14 | |
| P1433 | published in | Journal of Experimental & Clinical Cancer Research | Q13739415 |
| P1476 | title | Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review | |
| P478 | volume | 28 |
| Q86505685 | A case of fatal cetuximab-induced interstitial lung disease during the first weeks of treatment |
| Q38030496 | A rare but severe pulmonary side effect of cetuximab in two patients. |
| Q42908395 | Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses |
| Q89568332 | Anticancer therapy and lung injury: molecular mechanisms |
| Q38004033 | Cetuximab in non-melanoma skin cancer |
| Q34623949 | Cetuximab: a review of its use in squamous cell carcinoma of the head and neck |
| Q34198721 | Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancer |
| Q26830569 | Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets |
| Q36134904 | Efficacy and safety of target combined chemotherapy in advanced gastric cancer: a meta-analysis and system review |
| Q42696006 | Epidermal growth factor receptor and metastatic colorectal cancer: insights into target therapies |
| Q34499968 | Infectious complications in head and neck cancer patients treated with cetuximab: propensity score and instrumental variable analysis |
| Q47672858 | Interstitial lung disease secondary to Cetuximab in bladder cancer: an Oncologist's perspective |
| Q37696502 | Safety profile of new anticancer drugs. |
| Q37132805 | The role of epidermal growth factor receptor mutations and epidermal growth factor receptor-tyrosine kinase inhibitors in the treatment of lung cancer |
| Q38115675 | Treatment related severe and fatal adverse events with cetuximab in colorectal cancer patients: a meta-analysis |
| Q35285305 | Update on the role of imaging in management of metastatic colorectal cancer |
Search more.